UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.
Stocks · News reference
Filed: 2026-08-04 AccNo: 0001628280-26-052149 Size: 456 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.
RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $15 to $8.
Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $9.
U.S. stocks gain with Nasdaq up more than 2% on Tuesday. Dow up 1.79% to 54,129.35, Nasdaq up 2.22% to 26,490.24, S&P 500 up 1.64% to 7,725.48. Tech shares jump 3.8%, utilities down 0.5%. McDonald's beats earnings estimates. Ibotta, Backblaze, Corvex up, Adapthealth, Better Home & Finance, Clearpoint Neuro down.